Sequence Identity and Biotechnology Patents: How Similar Is Similar Enough?

A biotechnology invention may begin with a single nucleotide or amino acid sequence, but commercially meaningful protection rarely ends there. Once researchers identify a useful nucleic acid, protein, antibody, or other biological molecule, they commonly create variants containing substitutions, deletions, insertions, or other changes. Some variants retain the original activity; others may offer better stability, potency, expression, or manufacturability.

That scientific reality creates a central patent-drafting problem: how can a claim protect not only the sequence that was made and tested, but also related sequences that preserve the invention's useful characteristics? If the claim is limited to one exact sequence, a competitor may be able to avoid literal infringement by making relatively modest changes. If the claim reaches too far, however, it may encompass more than the specification supports and be invalid.

Understanding Sequence Identity

Sequence identity provides one way to navigate this problem. Instead of limiting a claim to a single disclosed sequence, an applicant may define a molecule by reference to a specified level of identity, such as at least 90%, 95%, or 99% identity to a designated sequence. Antibody claims, for example, may use identity thresholds to define a variable region, a heavy or light chain, or another sequence-based portion of the molecule. Since sequence identity depends on what is compared, how the sequences are aligned, whether gaps are permitted, and which calculation method is used, a well-prepared application should define the comparison with enough precision that the claim boundary can be understood and applied consistently.

Used carefully, sequence-identity language can encompass a family of related molecules without requiring every possible variant to be individually listed. It converts biological similarity into a structural claim limitation.

Why Sequence Identity Matters

Biological function does not require absolute sequence identity. A protein may tolerate substitutions at many positions without losing activity. Different nucleic-acid sequences may also encode the same protein because the genetic code is degenerate. Thus, a competitor may be able to alter a sequence while preserving substantially the same function.

The doctrine of equivalents may sometimes address a modified molecule that falls outside the literal wording of a claim but differs only insubstantially. Reliance on that doctrine, however, introduces a separate factual and legal inquiry and may be limited by prosecution-history estoppel and other constraints.

A properly drafted identity limitation can reduce that uncertainty. If a claim requires at least 95% identity under the stated comparison method, a molecule satisfying that threshold may fall within the claim literally. Sequence-identity language can therefore make claims more resistant to straightforward sequence-based design-arounds and reduce the need to rely on the doctrine of equivalents in an infringement action.

The Tension Between Breadth and Support

The same language that broadens protection can also create serious patentability concerns. A claim encompassing all proteins having at least 80% identity to one disclosed protein may cover an enormous and diverse set of sequences. Disclosure of one molecule does not necessarily show possession of that full group or teach skilled artisans how to make and use its full scope without undue experimentation.

The issue is not merely how low an identity threshold can be written into a claim. The more sequence space the claim covers, the stronger the need for a scientific basis for grouping those variants together. Broader coverage may also bring additional prior art within the claim and, if the claim encompasses naturally occurring molecules without a sufficient distinction from nature, may raise patent-eligibility concerns.

Selecting a percentage is therefore a substantive drafting decision, not a numerical exercise. The appropriate threshold depends on the technology, the variability of the molecule, the importance of particular residues or regions, the available experimental data, and the disclosure that can be provided.

Sequence Identity Is Not the Same as Function

Sequence identity does not necessarily predict function. A single amino acid substitution at a critical position may substantially alter or eliminate biological activity, while numerous substitutions at less important positions may have little effect. For this reason, biotechnology claims often combine structural and functional limitations. A claim might require both a specified degree of identity to a reference sequence and retention of a defined activity, binding property, catalytic function, or therapeutic effect. The identity requirement supplies a structural boundary, while the functional requirement focuses the claim on variants that preserve the feature that makes the invention useful.

This combination can be powerful, but it does not automatically cure an overbroad claim. The specification must still support that combination of structure and function across the full scope of the claim.

Drafting the Specification With Variants in Mind

Meaningful sequence-identity claims are often won or lost when the application is prepared. A specification that discloses one preferred sequence and merely states that variants are contemplated may provide a weak foundation for broader protection. Where variants matter commercially, the disclosure should explain why the claimed family is scientifically coherent.

Depending on the invention, useful support may include:

-     Representative variants spanning the intended range of claim scope;

-     Experimental results showing which variants retain the relevant activity;

-     Identification of conserved residues, motifs, domains, or complementarity-determining regions;

-     Discussion of positions that tolerate substitution, deletion, or insertion;

-     Examples of conservative and nonconservative substitutions; and

-     A clear explanation of the method used to calculate sequence identity.

Testing several thoughtfully selected variants may be more valuable than presenting a long list of hypothetical substitutions. The objective is to establish a credible relationship between the disclosed examples and the broader sequence space the claims are intended to cover.

Final Thoughts

Sequence identity is one of the most useful tools for claiming biotechnology inventions because it recognizes an important biological reality: useful molecules often exist as families of related sequences rather than as one immutable structure. But percentage identity is not simply a mechanism for making a claim broader.

Effective drafting requires a balance. The claim should encompass enough variation to discourage trivial design-arounds, while the specification should provide enough structural and functional information to justify that scope. The central question is therefore not merely how similar two sequences are. It is whether the patent disclosure provides a sound scientific and legal basis for claiming them as part of the same invention.

Disclaimer: This piece is provided for general informational purposes only and does not constitute legal advice. Patent issues are often complex and highly fact-specific, and no one should act on general information of this kind without consulting qualified patent counsel regarding the particular circumstances involved.